文献速递前列腺癌

原发肿瘤p53状态预测CRPC对阿比特龙和恩杂鲁胺的疗效

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-01-04

该回顾性分析纳入309例接受阿比特龙或恩杂鲁胺治疗的CRPC患者,其中101例有原发肿瘤组织可分析。p53核累积与更差的总生存和无进展生存显著相关,而PTEN缺失与生存无关。原发肿瘤p53失活可能预测新型激素治疗疗效不佳。

要点

  • 原发肿瘤p53核累积的CRPC患者接受阿比特龙或恩杂鲁胺后OS和PFS显著更短。
  • PTEN缺失状态与OS和PFS无显著差异。
  • 多变量分析中p53状态与PFS独立相关,OS的HR为2.19但95%CI含1。

核心结论

  • 原发肿瘤p53失活(而非PTEN缺失)可能预测CRPC患者对新型激素治疗(阿比特龙或恩杂鲁胺)的疗效较差。

研究设计与样本

  • 回顾性分析309例连续接受阿比特龙或恩杂鲁胺治疗的CRPC患者,其中101例(33%)有原发肿瘤组织可用于分析。
  • 采用经遗传学验证的免疫组化检测p53蛋白核累积和PTEN蛋白缺失,并对部分样本进行TP53突变测序确认。

主要发现

  • p53核累积组 vs 无p53核累积组:中位OS为16.7个月(95%CI 14-21.9)vs 31.2个月(95%CI 24.5-43.4),HR 2.32(95%CI 1.19-4.51),P=0.0018。
  • p53核累积组 vs 无p53核累积组:中位PFS为5.5个月(95%CI 3.2-9.9)vs 10.9个月(95%CI 8-15.2),HR 2.14(95%CI 1.20-3.81),P=0.0008。
  • PTEN状态与OS和PFS无显著差异。
  • 多变量分析中,p53状态与PFS独立相关(HR 2.15;95%CI 1.03-4.49;P=0.04),OS的HR为2.19(95%CI 0.89-5.40;P=0.087)。

临床怎么用

  • 对于CRPC患者,原发肿瘤p53核累积检测可能有助于预测阿比特龙或恩杂鲁胺的疗效。
  • PTEN缺失状态在此背景下未显示与生存的显著关联。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We tested whether tissue-based analysis of p53 and PTEN genomic status in primary tumors is predictive for subsequent sensitivity to abiraterone and enzalutamide in castration-resistant prostate cancer (CRPC). METHODS: We performed a retrospective analysis of 309 consecutive patients with CRPC treated with abiraterone or enzalutamide. Of these, 101 men (33%) had available primary tumor tissue for analysis. We screened for deleterious TP53 missense mutations and PTEN deletions using genetically validated immunohistochemical assays for nuclear accumulation of p53 protein and PTEN protein loss, with sequencing confirmation of TP53 mutations in a subset. Overall survival (OS) and progression-free survival (PFS) were compared between patients with and without p53 and/or PTEN alterations. RESULTS: Forty-eight percent of the evaluable cases had PTEN loss and 27% had p53 nuclear accumulation. OS and PFS did not differ according to PTEN status, but were significantly associated with p53 status. Median OS was 16.7 months (95% CI, 14-21.9 months) and 31.2 months (95% CI, 24.5-43.4) for men with and without p53 nuclear accumulation, respectively (HR 2.32; 95% CI 1.19-4.51; P = 0.0018). Similarly, median PFS was 5.5 months (95% CI, 3.2-9.9 months) and 10.9 months (95% CI, 8-15.2 months) in men with and without p53 nuclear accumulation, respectively (HR 2.14, 95%CI 1.20-3.81; P = 0.0008). In multivariable analyses, p53 status was independently associated with PFS (HR 2.15; 95% CI 1.03-4.49; P = 0.04) and a HR of 2.19 for OS (95% CI 0.89-5.40; P = 0.087). CONCLUSIONS: p53 inactivation in the primary tumor (but not PTEN loss) may be predictive of inferior outcomes to novel hormonal therapies in CRPC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Maughan BL, Guedes LB, Boucher K, et al. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 29302046. doi:10.1038/s41391-017-0027-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。